Patents Assigned to Virttu Biologics Limited
  • Publication number: 20210169955
    Abstract: An oncolytic herpes simplex virus is disclosed for use in a method of treating cancer, the method comprising administering one or more doses of an oncolytic herpes simplex virus effective to induce a Th1 immune response in the subject, and optionally administering a therapeutically effective amount of an immune checkpoint inhibitor.
    Type: Application
    Filed: September 3, 2020
    Publication date: June 10, 2021
    Applicant: VIRTTU BIOLOGICS LIMITED
    Inventor: Joe Conner
  • Patent number: 10813958
    Abstract: An oncolytic herpes simplex virus is disclosed for use in a method of treating cancer, the method comprising administering one or more doses of an oncolytic herpes simplex virus effective to induce a Th1 immune response in the subject, and optionally administering a therapeutically effective amount of an immune checkpoint inhibitor.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: October 27, 2020
    Assignee: Virttu Biologics Limited
    Inventor: Joe Conner
  • Publication number: 20200289590
    Abstract: A monocyte, monocyte derived cell or macrophage infected with an oncolytic herpes simplex virus is disclosed together with uses of such infected cells in the treatment of diseases such as cancer.
    Type: Application
    Filed: February 13, 2020
    Publication date: September 17, 2020
    Applicants: Virttu Biologics Limited, The University of Sheffield
    Inventors: Joe Conner, Munitta Muthana, Claire Elizabeth Lewis
  • Publication number: 20200078426
    Abstract: An oncolytic herpes simplex virus is disclosed for use in a method of treating cancer in a human subject, the method comprising administering to the human subject at least one dose of oncolytic herpes simplex virus by infusion to the blood, wherein the oncolytic herpes simplex virus reaches cells of the cancer in which it replicates.
    Type: Application
    Filed: September 17, 2019
    Publication date: March 12, 2020
    Applicant: VIRTTU BIOLOGICS LIMITED
    Inventor: Joe Conner
  • Publication number: 20200000861
    Abstract: Oncolytic herpes simplex virus for use in a method of treating cancer in a pediatric subject having a tumor are described, wherein the oncolytic herpes simplex virus is administered intratumorally.
    Type: Application
    Filed: June 20, 2019
    Publication date: January 2, 2020
    Applicant: Virttu Biologics Limited
    Inventors: Joe Conner, Timothy Cripe
  • Publication number: 20180071348
    Abstract: A monocyte, monocyte derived cell or macrophage infected with an oncolytic herpes simplex virus is disclosed together with uses of such infected cells in the treatment of diseases such as cancer.
    Type: Application
    Filed: March 11, 2016
    Publication date: March 15, 2018
    Applicants: VIRTTU BIOLOGICS LIMITED, THE UNIVERSITY OF SHEFFIELD
    Inventors: Joe CONNER, Munitta MUTHANA, Claire Elizabeth LEWIS
  • Patent number: 9085777
    Abstract: The present invention includes a method of generating a mutant Herpes Simplex Virus (HSV). In one embodiment, the generated HSV genome includes nucleic acid encoding a nucleic acid sequence of interest. In one step, a nucleic acid vector is provided which includes a nucleic acid encoding first and second site specific recombination sequences and a nucleic acid encoding a nucleic acid sequence of interest between said site specific recombination sequences an HSV is provided, the genome of which comprises third and fourth site specific recombination sequences In another step, the nucleic acid vector and HSV are contacted together with one or more recombinase enzymes capable of catalyzing site specific recombination between the site specific recombination sequences of said nucleic acid vector and said HSV. Another step includes identifying HSV containing the nucleic acid sequence of interest. In some embodiments, the methods are conducted in a cell-free system.
    Type: Grant
    Filed: May 4, 2007
    Date of Patent: July 21, 2015
    Assignee: Virttu Biologics Limited
    Inventor: Joe Conner
  • Patent number: 8980282
    Abstract: Herpes Simplex Viruses are disclosed having single-chain antibodies (scFv) embedded in the viral envelope via fusion with glycoprotein D and with glycoprotein H and L.
    Type: Grant
    Filed: April 2, 2008
    Date of Patent: March 17, 2015
    Assignee: Virttu Biologics Limited
    Inventor: Joe Conner
  • Patent number: 8969063
    Abstract: A herpes simplex virus is disclosed in which the herpes simplex virus genome comprises a nucleic acid sequence encoding an ING4 polypeptide.
    Type: Grant
    Filed: March 12, 2012
    Date of Patent: March 3, 2015
    Assignee: Virttu Biologics Limited
    Inventors: Joe Conner, Susanne Moira Brown
  • Patent number: 8778684
    Abstract: There is provided an HSV complex which comprises an avirulent HSV and a targeting agent which allows the HSV particle to infect and lyse a specific targeted cell. The inventors have found a way in which avirulent HSV can be targeted to disease cells, e.g. cancer cells, by incorporating an antibody binding domain into one or more viral glycoproteins.
    Type: Grant
    Filed: April 13, 2011
    Date of Patent: July 15, 2014
    Assignee: Virttu Biologics Limited
    Inventors: Susanne Moira Brown, Joe Conner
  • Patent number: 8530437
    Abstract: An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding an antisense to the squamous cell carcinoma related oncogene (asSCCRO); and an herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a short interfering ribonucleic acid (siRNA) molecule that is capable of repressing or silencing expression of squamous cell carcinoma related oncogene (SCCRO) nucleic acid or polypeptide are disclosed together with methods for generation and applications of such viruses.
    Type: Grant
    Filed: May 6, 2009
    Date of Patent: September 10, 2013
    Assignees: Sloan Kettering Institute for Cancer Research, Virttu Biologics Limited
    Inventors: Susanne Moira Brown, Paul Dunn, Bhuvanesh Singh, Ian Ganly
  • Publication number: 20120237999
    Abstract: A herpes simplex virus is disclosed in which the herpes simplex virus genome comprises a nucleic acid sequence encoding an ING4 polypeptide.
    Type: Application
    Filed: March 12, 2012
    Publication date: September 20, 2012
    Applicant: VIRTTU BIOLOGICS LIMITED
    Inventors: Joe Conner, Susanne Moira Brown
  • Publication number: 20120141418
    Abstract: Use as an anti-cancer agent of a mutant herpes simplex virus wherein the mutant virus comprises a modification in the ?34.5 gene in the long repeat region (RL) such that the ?34.5 gene is a non-functional, manufacture of medicaments and methods of testing cancer in mammals employing HSV mutant.
    Type: Application
    Filed: November 28, 2011
    Publication date: June 7, 2012
    Applicants: THE WISTAR INSTITUTE, Virttu Biologics Limited
    Inventors: Alasdair Roderick MacLean, Susanne Moira Brown, Nigel William Fraser, Bruce Paul Randazzo
  • Patent number: 8163292
    Abstract: A herpes simplex virus is disclosed in which the herpes simplex virus genome comprises a nucleic acid sequence encoding an ING4 polypeptide.
    Type: Grant
    Filed: February 15, 2008
    Date of Patent: April 24, 2012
    Assignee: Virttu Biologics Limited
    Inventors: Joe Conner, Susanne Moira Brown